日本研究人員在新一期美國(guó)《國(guó)家科學(xué)院學(xué)報(bào)》網(wǎng)絡(luò)版上報(bào)告說(shuō)，通過(guò)阻止骨髓細(xì)胞內(nèi)的某種蛋白質(zhì)與激素結(jié)合,，可防止大腸癌向肝臟轉(zhuǎn)移。
京都大學(xué)遺傳藥理學(xué)教授武藤誠(chéng)率領(lǐng)的研究小組在之前的研究中發(fā)現(xiàn),，部分含有蛋白質(zhì)“CCR1”的骨髓細(xì)胞會(huì)被大腸癌細(xì)胞分泌的激素吸引并與其結(jié)合在一起,，然后釋放出酶,。這種酶使正常的組織變得脆弱,，這樣癌細(xì)胞就容易轉(zhuǎn)移和浸潤(rùn)到肝臟組織內(nèi)部,。
在本次實(shí)驗(yàn)中，研究人員讓患有大腸癌的實(shí)驗(yàn)鼠攝入妨礙“CCR1”蛋白質(zhì)與激素結(jié)合的物質(zhì),，結(jié)果癌細(xì)胞的轉(zhuǎn)移受到了抑制,。與沒(méi)有攝入上述物質(zhì)的患病實(shí)驗(yàn)鼠相比，它們的平均生存期間延長(zhǎng)了約1倍,，達(dá)到62天,。研究人員還利用注入了人類大腸癌細(xì)胞的實(shí)驗(yàn)鼠進(jìn)行相同的實(shí)驗(yàn)，確認(rèn)了上述方法可產(chǎn)生同樣的抑制效果,。
武藤誠(chéng)指出：“這一發(fā)現(xiàn)有可能為預(yù)防大腸癌轉(zhuǎn)移和開(kāi)發(fā)治療方法作出貢獻(xiàn),。”(生物谷Bioon.net)
更多閱讀
人CC趨化因子受體1(CCR1)ELISA Kit報(bào)價(jià)/價(jià)格
信號(hào)轉(zhuǎn)導(dǎo)研究專題
生物谷推薦原文出處：
PNAS doi: 10.1073/pnas.1002372107
Inactivation of chemokine (C-C motif) receptor 1 (CCR1) suppresses colon cancer liver metastasis by blocking accumulation of immature myeloid cells in a mouse model
Takanori Kitamuraa,1, Teruaki Fujishitaa,1, Pius Loetscherb, Laszlo Reveszb, Hiroki Hashidac, Shinae Kizaka-Kondohd, Masahiro Aokia, and Makoto M. Taketoa,2
aDepartment of Pharmacology, Graduate School of Medicine, Kyoto University, Kyoto 606-8501, Japan;
bNovartis Institutes for BioMedical Research, Novartis Pharma AG, CH-4056 Basel, Switzerland;
cDepartment of Gastroenterological Surgery and Oncology, Kitano Hospital, Osaka 530-8480, Japan; and
dDepartment of Radiation Oncology and Image-Applied Therapy, Graduate School of Medicine, Kyoto University, Kyoto 606-8507, Japan
Recent reports have suggested critical roles of myeloid cells in tumor invasion and metastasis, although these findings have not led to therapeutics. Using a mouse model for liver dissemination, we show that mouse and human colon cancer cells secrete CC-chemokine ligands CCL9 and CCL15, respectively, and recruit CD34+ Gr-1? immature myeloid cells (iMCs). They express CCL9/15 receptor CCR1 and produce matrix metalloproteinases MMP2 and MMP9. Lack of the Ccr1, Mmp2, or Mmp9 gene in the host dramatically suppresses outgrowths of disseminated tumors in the liver. Importantly, CCR1 antagonist BL5923 blocks the iMC accumulation and metastatic colonization and significantly prolongs the survival of tumor-bearing mice. These results suggest that CCR1 antagonists can provide antimetastatic therapies for patients with disseminated colon cancer in the liver.
